Cambridge, UK, 18 June 2018 – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell engaging therapeutics, today announces that Eva-Lotta Allan has been appointed as Non-Executive Director of the Company with immediate effect.
Eva-Lotta has over 30 years’ experience in the biopharmaceutical industry, most recently as Chief Business Officer at clinical-stage T-cell receptor company, Immunocore. During her five years at Immunocore she raised $320 million in a Series A round, established significant strategic partnerships with top pharmaceutical companies and was elected to the Board of the BIA. She has also served on a number of other Boards in both private and publicly held companies during her career, and is currently a non-executive director for Targovax ASA.
Prior to Immunocore, Eva-Lotta was Chief Business Officer at Ablynx NV. At Ablynx, she closed a number of deals of significant value with premier pharmaceutical companies bringing in over €160 million in non-dilutive cash to the company, held strategic and operational responsibilities, and contributed to its successful IPO on Euronext in 2007.
Kevin Johnson, Chairman of the Board of Directors at Crescendo Biologics, said:
“Eva Lotta adds a tremendous network and expertise in deal making as she successfully has demonstrated in her operative business development roles at Vertex, Ablynx and Immunocore. As an independent industry expert, she also brings vast experience in immuno-oncology and in the development of multifunctional biologics - an ideal combination for Crescendo.”
Eva-Lotta Allan, Non-Executive Director, also commented:
“With Crescendo’s recent $70 million Series B financing, it is in a strong position to develop its exciting pipeline of potent, multi-functional Humabody® therapeutics in oncology. I look forward to working with the Crescendo team as we continue to build on the significant achievements delivered to date."
About Crescendo Biologics
Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody® therapeutics in oncology with a focus on innovative targeted T-cell approaches.
Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment, thereby avoiding systemic toxicity. This highly modular format can be re-configured to create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting any of a range of alternative tumour-specific markers.
The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® VH). These robust molecules can be configured to optimally engage therapeutic targets delivering novel biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches.
Crescendo Biologics is pursuing novel Humabody®-based product opportunities, through in-house development and strategic partnerships, including multi-functional immuno-oncology modulators and Humabody® drug conjugates (HDCs), the next generation of ADCs. Humabody®-based formats can also be applied across a range of non-cancer indications.
Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital, Astellas and EMBL ventures.
For more information, please visit the website: www.crescendobiologics.com.
Issued for and on behalf of Crescendo Biologics by Instinctif Partners.
For more information please contact: firstname.lastname@example.org.